Coming Soon

Canine Lymphoma
Lymphoma is one of the most commonly encountered cancers in the dog. The incidence of canine lymphoma has steadily increased with approximately 84 per 10,000 dogs diagnosed each year. This randomized, double-masked, placebo-controlled, GCP pivotal field study is evaluating the effectiveness and safety of verdinexor for the treatment of naïve or first relapse stages II, III and IV lymphoma in client owned dogs. Diagnosis of lymphoma must be confirmed by cytology or biopsy for the dog to be eligible for this study. Dogs will be randomized to receive the investigational veterinary product or a placebo treatment (tablets) to be administered with food twice weekly at least 72 hours apart for 8 weeks. After receiving treatment in-hospital on Day 0, the dog will be required to return to the study site on Days 7, 14, 28, 42, and 56 for follow up evaluation visits. Owners will be required to report and record abnormal daily observations and dosing using a phone app at home throughout the study.
- Your dog has naïve or first relapse lymphoma
- Your dog is over 1 year old and weighs more than 9kgs (~20lbs)
- Your dog has a confirmed diagnosis of B or T cell lymphoma in stage II III or IV
- Your dog has a ECOG performance status of less than or equal to 1
Funding for the study includes:
Initial Study Screening
Scheduled Study Lab Work
Recheck visits and Exams
Managment of side effects
MALVERN, PA
RECRUITING

Canine Diabetes
Diabetes mellitus is an important health problem in both dogs and people. Type 1 diabetes (T1D) in people is caused by an attack of the body’s own immune system on cells in the pancreas. Diabetes in dogs is thought to be similar in some ways to T1D in people, but there is still much more to learn about the causes of diabetes in dogs as well as better ways to prevent and treat the disease. The purpose of this study is to learn more about metabolism and immune function in diabetic dogs.
- Your dog has been recently diagnosed with canine diabetes
- Your dog has other endocrine related disease or is a non-spayed female
Free Participation
Enrolled pets receive free:
- Bloodwork
- Urine Sample
- Repeated Vet Checkups
GAINESVILLE, FL
ENROLLING

Complement Inhibition in Canine IMHA
Immune-mediated hemolytic anemia (IMHA) is a common disease that affects all breeds of dogs and can be fatal. In the severe form of the disease complement activation causes red blood cells to be broken down in the bloodstream. At present no therapies for IMHA target this complement activation. We have confirmed that an FDA licensed formulation of C1-INH is safe for dogs and effectively inhibits canine complement mediated hemolysis. We hope this will translate into a beneficial effect in dogs with intravascular red cell breakdown due to IMHA.
- Your dog has been diagnosed with IMHA
ITHACA, NY
ENROLLING



DCM in Dobermans
Dilated Cardiomyopathy (DCM) is a disease of heart muscle that results in a decreased ability of the heart to pump blood. The prognosis for DCM is often poor, with a less than 50% survival rate one year after clinical signs develop, unless a reversible underlying cause is identified. There is no available cure for Dilated Cardiomyopathy, current techniques focus on extending survival time as long as possible. However the focus of this clinical trial is to evaluate a potential curative treatment for cardiomyopathy in the Doberman Pinscher.
- Your dog has been diagnosed with dilated cardiomyopathy
- Your dog has no other heart conditions
Free Participation
Enrolled pets receive free:
- Free participation
- bloodwork
- ECHO
- ECG
- Repeated vet checkups
GAINESVILLE, FL
ENROLLING

Determining the Transcriptome of Canine Soft Tissue Sarcoma
Soft tissue sarcomas (STS) are tumors that arise from various skin and connective tissues under the skin, such as fat, muscle, cartilage, nerves, or small blood vessels. These tumors can occur from any site on the body and commonly regrow after tumor removal. While surgical removal and other therapies are available to treat these tumors, little is known as to why the occur in the first place. Dr. Andrew Miller and his lab are collecting samples of canine soft tissue sarcomas in order to determine their RNA molecules, otherwise known as transcriptomes. This information will one day lead to new treatments and preventives for these tumors.
- Your dog needs surgery to remove an STS
ITHACA, NY
ENROLLING



Dietary Trial for Cats with IBD or GI Lymphoma
The clinical signs in some cats with chronic enteropathy (chronic vomiting and/or diarrhea) can be reversed with dietary management using a specially formulated diet. It is not clear why some cats respond to diet, or what the optimal composition of the diet for cats with chronic enteropathy should be. We want to know if diets containing proteins that are selected to minimize immune responses and fortified in Vitamin B12 and natural anti-inflammatory agents (prebiotics and curcumin) are better than conventional diets for cats with chronic enteropathy.
- Any Cat with signs of chronic GI disease
ITHACA, NY
ENROLLING



MALVERN, PA
RECRUITING
Canine Lymphoma
Lymphoma is one of the most commonly encountered cancers in the dog. The incidence of canine lymphoma has steadily increased with approximately 84 per 10,000 dogs diagnosed each year. This randomized, double-masked, placebo-controlled, GCP pivotal field study is evaluating the effectiveness and safety of verdinexor for the treatment of naïve or first relapse stages II, III and IV lymphoma in client owned dogs. Diagnosis of lymphoma must be confirmed by cytology or biopsy for the dog to be eligible for this study. Dogs will be randomized to receive the investigational veterinary product or a placebo treatment (tablets) to be administered with food twice weekly at least 72 hours apart for 8 weeks. After receiving treatment in-hospital on Day 0, the dog will be required to return to the study site on Days 7, 14, 28, 42, and 56 for follow up evaluation visits. Owners will be required to report and record abnormal daily observations and dosing using a phone app at home throughout the study.
- Your dog has naïve or first relapse lymphoma
- Your dog is over 1 year old and weighs more than 9kgs (~20lbs)
- Your dog has a confirmed diagnosis of B or T cell lymphoma in stage II III or IV
- Your dog has a ECOG performance status of less than or equal to 1
Funding for the study includes:
Initial Study Screening
Scheduled Study Lab Work
Recheck visits and Exams
Managment of side effects

GAINESVILLE, FL
ENROLLING
Canine Diabetes
Diabetes mellitus is an important health problem in both dogs and people. Type 1 diabetes (T1D) in people is caused by an attack of the body’s own immune system on cells in the pancreas. Diabetes in dogs is thought to be similar in some ways to T1D in people, but there is still much more to learn about the causes of diabetes in dogs as well as better ways to prevent and treat the disease. The purpose of this study is to learn more about metabolism and immune function in diabetic dogs.
- Your dog has been recently diagnosed with canine diabetes
- Your dog has other endocrine related disease or is a non-spayed female
Free Participation
Enrolled pets receive free:
- Bloodwork
- Urine Sample
- Repeated Vet Checkups

ITHACA, NY
ENROLLING


Complement Inhibition in Canine IMHA
Immune-mediated hemolytic anemia (IMHA) is a common disease that affects all breeds of dogs and can be fatal. In the severe form of the disease complement activation causes red blood cells to be broken down in the bloodstream. At present no therapies for IMHA target this complement activation. We have confirmed that an FDA licensed formulation of C1-INH is safe for dogs and effectively inhibits canine complement mediated hemolysis. We hope this will translate into a beneficial effect in dogs with intravascular red cell breakdown due to IMHA.
- Your dog has been diagnosed with IMHA

GAINESVILLE, FL
ENROLLING
DCM in Dobermans
Dilated Cardiomyopathy (DCM) is a disease of heart muscle that results in a decreased ability of the heart to pump blood. The prognosis for DCM is often poor, with a less than 50% survival rate one year after clinical signs develop, unless a reversible underlying cause is identified. There is no available cure for Dilated Cardiomyopathy, current techniques focus on extending survival time as long as possible. However the focus of this clinical trial is to evaluate a potential curative treatment for cardiomyopathy in the Doberman Pinscher.
- Your dog has been diagnosed with dilated cardiomyopathy
- Your dog has no other heart conditions
Free Participation
Enrolled pets receive free:
- Free participation
- bloodwork
- ECHO
- ECG
- Repeated vet checkups

ITHACA, NY
ENROLLING


Determining the Transcriptome of Canine Soft Tissue Sarcoma
Soft tissue sarcomas (STS) are tumors that arise from various skin and connective tissues under the skin, such as fat, muscle, cartilage, nerves, or small blood vessels. These tumors can occur from any site on the body and commonly regrow after tumor removal. While surgical removal and other therapies are available to treat these tumors, little is known as to why the occur in the first place. Dr. Andrew Miller and his lab are collecting samples of canine soft tissue sarcomas in order to determine their RNA molecules, otherwise known as transcriptomes. This information will one day lead to new treatments and preventives for these tumors.
- Your dog needs surgery to remove an STS

ITHACA, NY
ENROLLING


Dietary Trial for Cats with IBD or GI Lymphoma
The clinical signs in some cats with chronic enteropathy (chronic vomiting and/or diarrhea) can be reversed with dietary management using a specially formulated diet. It is not clear why some cats respond to diet, or what the optimal composition of the diet for cats with chronic enteropathy should be. We want to know if diets containing proteins that are selected to minimize immune responses and fortified in Vitamin B12 and natural anti-inflammatory agents (prebiotics and curcumin) are better than conventional diets for cats with chronic enteropathy.
- Any Cat with signs of chronic GI disease
Find Patient
Trials Faster.
Make it easier for you to discover, learn, and recommend clinical trials to your patients. Our tools allow you to quickly screen available trials based on specific patient criteria, and get detailed information to feel confident in suggesting them to your clients.